Objective To investigate the clinical efficacy of dual bronchodilators [long-acting muscarinic antagonists（LAMA） + long-acting β2 agonist（LABA）] combined with Sanzi Zhike capsule in the treatment of stable chronic obstructive pulmonary disease（COPD） and its effects on the patients’ pulmonary function and adverse reactions. Methods Eighty-six patients with stable COPD treated in a hospital in Dalian from January 2019 to May 2021 were selected for the study. The random number table method was used to divide the patients into observation and control groups

with 43 cases in each group. Patients in the control group were treated with umeclidinium-vilanterol powder for inhalation

and patients in the observation group were treated with Sanzi cough capsules on top of the control group. The scores of the COPD Assessment Tool（CAT） were compared before and after treatment; the forced expiratory volume in the first second（FEV1）

forced vital capacity（FVC）

FEV1/FVC

and the levels of reduced glutathione（GSH）

malondialdehyde（MDA） and superoxide dismutase（SOD） were compared between the two groups. The incidence of adverse reactions was compared between the two groups. Results Before treatment

there was no statistically significant difference in CAT scores

FEV1

FVC

FEV1/FVC and GSH

MDA and SOD levels between the 2 groups（P>0.05）. After treatment

CAT scores and MDA levels of patients in the two groups were lower than those before treatment and lower in the observation group than in the control group

with statistically significant differences（P<0.05）

while the FEV1

FVC

FEV1/FVC and GSH and SOD levels of patients in the two groups were higher than those before treatment and higher in the observation group than in the control group

with statistically significant differences（P<0.05）. There was no statistically significant difference in the incidence of adverse reactions between the 2 groups（P>0.05）. Conclusion LAMA/LABA combined with Sanzi cough capsules is effective in the treatment of stable COPD. It can effectively improve the pulmonary function of patients and reduce the oxidative stress response of the patients’ bodies with high safety

and is worthy of clinical promotion.